The FDA Drugs@FDA database holds 29,135 distinct applications spanning nine decades of drug regulation. Of those, 22,805 (78.3%) are abbreviated new drug applications (ANDAs) for generics, 5,855 (20.1%) are new drug applications (NDAs) for novel products, and 475 (1.6%) are biologics license applications (BLAs). Watson Labs — now part of Teva — leads all sponsors with 902 applications. And 47.3% of all products ever approved have since been discontinued.
This analysis draws on the FDA Drugs@FDA database, which records all approved prescription, over-the-counter, and discontinued drug products, including their application numbers, sponsors, submission histories, and product-level details.
The application mix: 78% generic, 20% novel, 2% biologic
| Application type | Count | Share |
|---|---|---|
| ANDA (generic) | 22,805 | 78.3% |
| NDA (new drug) | 5,855 | 20.1% |
| BLA (biologic) | 475 | 1.6% |
The generic-to-novel ratio of nearly 4:1 reflects the structural economics of the US drug market. Each novel product that achieves commercial success generates multiple generic entrants over its lifecycle. A single branded drug may spawn 10, 20, or more ANDA filings as generic manufacturers compete for market share after patent expiry and exclusivity expiration.
Among the 51,337 individual products (dosage forms, strengths, and package sizes) across all applications, the marketing status breakdown reveals the industry's churn:
| Marketing status | Products | Share |
|---|---|---|
| Prescription | 25,867 | 50.4% |
| Discontinued | 23,229 | 45.2% |
| Tentative Approval | 1,446 | 2.8% |
| Over-the-counter | 795 | 1.6% |
Nearly half of all products ever approved — 47.3% of those with Prescription or Discontinued status — are no longer marketed. This reflects a combination of generic competition driving originator withdrawal, formulation consolidation, and commercial decisions to discontinue low-volume products.
The top sponsors: generic manufacturers dominate volume
The top 20 sponsors by application count hold 22.8% of all applications. The list is overwhelmingly generic:
| Sponsor | Applications | Share | Cumulative |
|---|---|---|---|
| Watson Labs (Teva) | 902 | 3.1% | 3.1% |
| Hikma | 561 | 1.9% | 5.0% |
| Chartwell Rx | 476 | 1.6% | 6.7% |
| Hospira (Pfizer) | 467 | 1.6% | 8.3% |
| Sandoz (Novartis) | 440 | 1.5% | 9.8% |
| Fresenius Kabi USA | 334 | 1.1% | 10.9% |
| Rising | 329 | 1.1% | 12.0% |
| Teva | 323 | 1.1% | 13.2% |
| Pharmacobedient | 312 | 1.1% | 14.2% |
| Aurobindo Pharma Ltd | 275 | 0.9% | 15.2% |
| Apotex | 259 | 0.9% | 16.1% |
| ANI Pharmaceuticals | 248 | 0.9% | 16.9% |
| Mylan (Viatris) | 232 | 0.8% | 17.7% |
| Aurobindo Pharma | 232 | 0.8% | 18.5% |
| Zydus Pharmaceuticals | 228 | 0.8% | 19.3% |
| Lupin | 219 | 0.8% | 20.0% |
| Amneal | 214 | 0.7% | 20.8% |
| PH Health | 203 | 0.7% | 21.5% |
| Alembic | 203 | 0.7% | 22.2% |
| Dr Reddy's | 195 | 0.7% | 22.8% |
Seven of the top 20 sponsors are India-headquartered companies (Aurobindo appears twice due to two entity registrations). Among generic ANDA sponsors specifically, the same companies hold 23.0% of all ANDA filings, with Watson Labs alone holding 890 ANDAs (3.9% of all generics).
NDA sponsors: where innovation concentrates
Among the 5,855 NDA applications, the sponsor landscape shifts to innovator companies:
| NDA Sponsor | Applications |
|---|---|
| Novartis | 171 |
| Pfizer | 159 |
| AbbVie | 127 |
| Hospira | 108 |
| Baxter Healthcare | 103 |
| B Braun | 101 |
| GlaxoSmithKline | 97 |
| Sanofi Aventis US | 93 |
| Bausch | 73 |
| Lilly | 73 |
Novartis and Pfizer lead with 171 and 159 NDAs respectively. These counts include supplement filings for new indications, dosage forms, and formulation changes over decades, so a single molecule may generate multiple NDA application numbers. Hospira's inclusion (108 NDAs) reflects its legacy as a hospital products and injectable-medicine manufacturer before its acquisition by Pfizer.
BLA sponsors: the biologics landscape
The 475 BLA applications represent the fastest-growing segment of the database. The sponsor list reflects the biologics revolution:
| BLA Sponsor | BLAs |
|---|---|
| Genentech | 18 |
| Genentech Inc | 14 |
| Amgen Inc | 13 |
| Novo Nordisk Inc | 12 |
| Janssen Biotech | 11 |
| Eli Lilly and Co | 10 |
| Samsung Bioepis | 10 |
| Regeneron | 8 |
| Ferring | 8 |
| Amgen | 8 |
| Celltrion Inc | 8 |
| Sandoz Inc | 7 |
| Bristol Myers Squibb | 7 |
| EMD Serono | 7 |
| AstraZeneca AB | 7 |
Genentech (combined across entity names) holds 32 BLAs, making it the single largest biologics applicant in the database. The biosimilar presence is notable: Samsung Bioepis (10 BLAs), Celltrion (8), and Sandoz (7) together hold 25 BLAs, representing biosimilar manufacturers that have successfully navigated the 351(k) pathway.
The approval trend: generics surge, biologics accelerate
Looking at original approvals (ORIG-1 submissions with AP status) by year since 2000:
| Year | NDA | ANDA | BLA | Total |
|---|---|---|---|---|
| 2000 | 105 | 243 | 6 | 354 |
| 2002 | 92 | 316 | 8 | 416 |
| 2004 | 120 | 366 | 11 | 497 |
| 2006 | 103 | 352 | 5 | 460 |
| 2008 | 87 | 458 | 5 | 550 |
| 2010 | 85 | 429 | 9 | 523 |
| 2012 | 90 | 512 | 9 | 611 |
| 2014 | 112 | 425 | 12 | 549 |
| 2016 | 102 | 613 | 15 | 730 |
| 2017 | 147 | 840 | 24 | 1,011 |
| 2018 | 155 | 813 | 24 | 992 |
| 2019 | 133 | 826 | 23 | 982 |
| 2020 | 110 | 752 | 22 | 884 |
| 2021 | 103 | 628 | 21 | 752 |
| 2022 | 106 | 737 | 25 | 868 |
| 2023 | 107 | 768 | 29 | 904 |
| 2024 | 92 | 717 | 44 | 853 |
| 2025 | 112 | 659 | 52 | 823 |
| 2026 (partial) | 35 | 325 | 14 | 374 |
Three structural trends are visible:
The generic surge (2016–2019). ANDA approvals peaked at 840 in 2017, driven by the first wave of blockbuster generic entries following patent cliffs for drugs like Lipitor, Nexium, and Crestor. FDA's push to accelerate generic approvals under the Generic Drug User Fee Act (GDUFA) contributed to the doubling of annual ANDA approvals between 2014 and 2017.
The biologic acceleration (2023–2025). BLA approvals rose from 29 in 2023 to 44 in 2024 and 52 in 2025 — a 79% increase in two years. This surge reflects the maturation of the biosimilar pipeline (Samsung Bioepis, Celltrion, Sandoz, Coherus) alongside novel biologics approvals. CDER approved 46 novel drugs in 2025, including 12 biologics, and 20 novel drugs in the first five months of 2026 alone.
The ANDA decline (2022–2025). Generic approvals dropped from 768 in 2023 to 659 in 2025, a 14.2% decline. This likely reflects the depletion of near-term patent cliff opportunities, increased competition thinning the economic case for later ANDA entrants, and FDA's tightening of manufacturing quality standards for generic facilities.
Dosage forms and routes: tablets dominate
At the product level (51,337 individual products across all applications):
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 21,278 | 41.5% |
| Injectable | 8,681 | 16.9% |
| Capsule | 5,531 | 10.8% |
| Solution | 3,169 | 6.2% |
| Tablet, extended release | 2,749 | 5.4% |
| Capsule, extended release | 1,277 | 2.5% |
| Powder | 693 | 1.3% |
| Cream | 660 | 1.3% |
| Solution/drops | 654 | 1.3% |
Tablets (including extended-release and delayed-release variants) account for over 49% of all products. Injectables, the second-largest category, reflect the hospital and specialty drug segments where both branded biologics and generic sterile injectables compete.
By route of administration, oral products (34,338, 66.9%) dominate overwhelmingly, followed by injection (7,770, 15.1%), intravenous (2,045, 4.0%), and topical (1,858, 3.6%).
Submission patterns: supplements dwarf originals
The database records 186,593 total submission actions across all applications. Original submissions (ORIG) account for 26,445 (14.2%), while supplements (SUPPL) account for 160,124 (85.8%). This 6:1 supplement-to-original ratio reflects the post-approval lifecycle: each approved application generates multiple supplements for new indications, dosage forms, labeling updates, manufacturing changes, and other post-approval modifications over its commercial lifetime.
Of all submissions, 185,700 (99.5%) were approved and 1,168 received tentative approval, meaning the product meets quality standards but cannot be marketed in the US due to existing patents or exclusivity.
What this means for pharmaceutical strategy
1. The generic filing window is narrowing. With ANDA approvals declining from 840 in 2017 to 659 in 2025, later entrants face diminishing returns. First-to-file ANDA holders with 180-day exclusivity capture the bulk of generic profits; subsequent filers compete on thin margins. Generic companies should prioritize complex generics (injectables, inhalers, transdermals) where the technical barriers limit competition.
2. BLA filings are the growth vector. The 79% increase in BLA approvals from 2023 to 2025 signals that biosimilar and novel biologic filings will continue to accelerate. Sponsors planning BLA submissions should expect increased competition for review resources and plan for longer pre-approval inspection timelines as FDA's biologics inspection capacity adapts to higher volumes.
3. Product discontinuation creates market opportunities. With 47.3% of approved products discontinued, there are niche openings for generic manufacturers to supply discontinued products that still have clinical demand — particularly in hospital injectables, where sterile manufacturing capability creates a barrier to entry.
4. The supplement lifecycle is where regulatory investment compounds. The 6:1 supplement-to-original ratio means that regulatory affairs teams spend the vast majority of their effort on post-approval changes. Companies that invest in efficient supplement filing processes — including electronic CMC supplements and established condition frameworks under ICH Q12 — gain a structural advantage in bringing label expansions and manufacturing improvements to market faster.
5. Oral solid dosage is commoditized; complex dosage forms carry premium. With 49% of all products as tablets, the oral solid market is intensely competitive. Growth areas include extended-release formulations, injectables, and specialty dosage forms where the combination of manufacturing complexity and regulatory expertise creates defensible market positions.
Sources
FDA Drugs@FDA database; analysis by PharmaDossier, run date 2026-06-10. Data includes all approved NDAs, ANDAs, and BLAs with submission and product details. https://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-data-files
FDA, "Novel Drug Approvals for 2025." https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025
FDA, "Advancing Health Through Innovation: New Drug Therapy Approvals 2025." https://www.fda.gov/media/190705/download
FDA, "Novel Drug Approvals for 2026." https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026
C&EN, "FDA's new drug approvals dipped in 2025," January 2026. https://cen.acs.org/pharmaceuticals/FDAs-new-drug-approvals-dipped/104/web/2026/01
